Daren Tang (600329.SH) announced its 2023 annual results, with net profit of 987 million yuan, an increase of 14.49% over the previous year. It plans to distribute 10 to 12.8 yuan
According to the Zhitong Finance App, Daren Tang (600329.SH) disclosed the 2023 annual report. The company achieved revenue of 8.222 billion yuan in 2023, a year-on-year decrease of 0.33%; net profit to mother of 987 million yuan, an increase of 14.49%; deducted non-net profit of 952 million yuan, an increase of 23.8%; and basic earnings per share of 1.28 yuan. The company plans to distribute a cash dividend of 12.8 yuan (tax included) for every 10 shares to all shareholders. In 2023, the company will firmly implement “focus on the market, effective innovation, organizational governance, co-creation and sharing, drive both industry and finance, control capital and loss, digital empowerment, and cultural goods
Singapore-listed Manufacturers Book Mixed Returns in Early 2024
Singapore's manufacturing sector moderated in 2023, with a 4.3% contraction, reversing the 2.7% growth in 2022. Looking forward, the Ministry of Trade and Industry (MTI) expect that as global electronics demand recovers, Singapore's manufacturing and trade-related sectors will see a gradual improvement in growth.
Portion of Tianjin Pharmaceutical Controlling Shareholder's Shares Placed Under Judicial Freeze
A portion of Tianjin Pharmaceutical (SGX:T14) controlling shareholder Tianjin Pharmaceutical Holdings' shares have been placed under judicial freeze, according to a Tuesday bourse filing. The shares,
Tianjin Pharmaceutical Taps Affiliate for Brand Promotion
Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) will engage Tianjin Pharmaceutical Group Marketing for brand promotion and marketing business expansion. Under the agreement, Tianjin Pharmaceutical
Tianjin Pharmaceutical Hires Contractor for Renovation of Workshop, Warehouses
Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) entered into a construction contract with Tianjin Pharmaceutical Design Institute for the decoration of a workshop and renovation of warehouses. Unde
Da Ren Tang (600329.SH): Intends to sign a contract with Tianjin Pharmaceutical Design Institute Co., Ltd.
Gelonghui (600329.SH) announced on December 19丨Da Rentang () announced that in order to integrate the medicinal herbs and tablet business lines and achieve integrated management of tablets and related businesses, the company plans to build a new tablet production workshop, decoction center and supporting facilities in the existing Qingguang South Reservoir area, and upgrade warehouses in the northern storage area. Based on this plan, the company plans to carry out the “Jinyao Da Rentang Drink Factory Relocation and Renovation Project - Frying Workshop Single Project” and the “Jinyao Da Rentang Pharmaceutical Company Qingguang Reservoir North Reservoir Area Renovation Project - 27 #29 #43 #库改造工程” project. According to the bidding results, Tianjin Pharmaceutical Design Institute Co., Ltd.
Da Ren Tang (600329.SH): Some products note the lifting of restrictions and adjustments and changes in the “National Health Insurance Catalogue”
<国家基本医疗保险、工伤保险和生育保险药品目录(2023年)>Gelonghui, December 15|Da Rentang (600329.SH) announced that the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the “Notice on Issuance”. In the “2023 Medical Insurance Catalogue”, the comment restrictions on some products of Jinyao Da Rentang Group Co., Ltd. have been lifted or adjusted. The content of the comment restrictions on the company's related products has been partially adjusted, and some restrictions have been lifted, which is expected to have a positive effect on the future promotion and application of the company's related products. More patients will benefit from the adjustment of health insurance restrictions
Da Ren Tang (600329.SH): The shareholding structure of the controlling shareholder has changed
Gelonghui (600329.SH) announced on November 22|Da Rentang () announced that it recently received the “Notice Letter on Changes in the Shareholding Structure of Pharmaceutical Group” from the controlling shareholder, Tianjin Pharmaceutical Group Co., Ltd., which adjusted the original pharmaceutical group equity transfer plan according to the overall deployment and strategic planning arrangements of the superior units of the pharmaceutical group's shareholders. The equity structure of the Pharmaceutical Group has changed, and the registration of industrial and commercial changes in equity matters has been completed. Tianjin Bohai Guoxin Technology Co., Ltd., a shareholder of Pharmaceutical Group, used its 33% stake in Pharmaceutical Group to increase capital to its wholly-owned subsidiary Tianjin Guoyu Enterprise Management Co., Ltd.
Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a good company can see its share price rise well over 100%. For example, the Tianji
Private Companies Own 43% of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) Shares but Retail Investors Control 46% of the Company
Is Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Da Ren Tang (600329.SH): Drugs such as Da Ren Tang Qingfeng Detox Tablets and Pediatric Fitness Tablets can be selected
Gelonghui November 2 | Da Rentang (600329.SH) said on the investor interactive platform that mycoplasma and viral infections are mainly determined by the environment and autoimmunity. Avoiding high-risk environments is a prerequisite, and improving the body's immunity is also critical. Medications such as Daren Tang Qingfeng antidote tablets and pediatric fitness tablets can be used as options.
Da Ren Tang (600329.SH): Net profit for the first three quarters was 858 million yuan, up 17.73% year on year
On October 30, Gelonghui (600329.SH) disclosed its report for the third quarter of 2023. In the first three quarters, the company achieved revenue of 5.793 billion yuan, an increase of 4.13% over the previous year; net profit of 858 million yuan, an increase of 17.73% over the previous year; net profit after deduction of 842 million yuan, an increase of 29.8%; and basic earnings per share of 1.11 yuan.
Should You Be Adding Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Lisheng Pharmaceutical (002393.SZ): 15% of the shares of the listed and transferred finance company were delisted and transferred by Jinyao Da Rentang
Glonghui, Oct. 9, 丨 Lisheng Pharmaceutical (002393.SZ) announced that it previously revealed that the company plans to publicly list and transfer 15% of the shares held by the company's participating company Tianjin Pharmaceutical Group Finance Co., Ltd. (“target company” or “finance company”) at the Tianjin Property Exchange Center at a price of RMB 87.823,386 million. The equity transfer was publicly listed at the Tianjin Property Exchange Center from August 28, 2023 to September 22, 2023. During the listing period, only one company signed up for delisting, namely Jinyao Da Rentang Group Co., Ltd. (“Jinyao Da Rentang” for short). This was the intention
Da Ren Tang (600329.SH): Plans to transfer 15% of the shares in the finance company for RMB 87.823,800
Gelonghui September 11丨Da Rentang (600329.SH) announced that the company plans to transfer 15% of the shares of Tianjin Pharmaceutical Group Finance Co., Ltd. through a public delisting method. The delisting price is RMB 87.823,86 million. If the transaction is successfully completed, the company's shareholding ratio in the finance company will be changed from 15% to 30%. A finance company is a non-bank financial institution established with the approval of the China Banking Regulatory Commission to provide a financing platform, fund management and settlement platform for the company.
Da Ren Tang (600329.SH): In the future, the medicinal materials most needed by the company will also vigorously promote the construction of dozens of GAP bases
Da Ren Tang (600329.SH) released investor research and reception records. Here are some of the main issues and companies exchanged...
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
It is hard to get excited after looking at Tianjin Pharmaceutical Da Ren Tang Group's (SGX:T14) recent performance, when its stock has declined 9.0% over the past three months. However, stock prices
Tianjin Pharmaceutical's Attributable Profit Rises 20% in Q2
Tianjin Pharmaceutical Da Ren Tang Group's (SGX:T14, SHA:600329) profit attributable to owners of the parent rose 20% to 321.7 million yuan in the second quarter from 269.2 million yuan a year ago. Ea
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SGX:T14) Intrinsic Value Is Potentially 20% Below Its Share Price
Key Insights The projected fair value for Tianjin Pharmaceutical Da Ren Tang Group is US$1.57 based on 2 Stage Free Cash Flow to Equity Current share price of US$1.97 suggests Tianjin Pharmaceutical
No Data